Daniel Meireles, Luísa Neiva Araújo, Marta Nascimento, L. Pinho, A. C. Freitas, A. Almeida, Cármen Carvalho, E. Proença
{"title":"Terapêutica com surfactante em recém-nascidos prematuros: tendência para uma abordagem menos invasiva","authors":"Daniel Meireles, Luísa Neiva Araújo, Marta Nascimento, L. Pinho, A. C. Freitas, A. Almeida, Cármen Carvalho, E. Proença","doi":"10.25753/BIRTHGROWTHMJ.V30.I1.19182","DOIUrl":null,"url":null,"abstract":"Introduction: Minimally invasive surfactant therapy (MIST) is a surfactant administration procedure that intends to reduce intubations and associated risks. The aim of this study was to compare MIST with INtubation-SURfactant-Extubation (INSURE) technique. \nMaterial and methods: Retrospective analysis (from January 2015 to June 2019) of preterm infants on nasal continuous positive airway pressure (nCPAP) treated with surfactant.\nResults: Fifty-four preterm infants were included and divided in two groups: MIST (n=34) and INSURE (n=20). No significant differences were found between groups regarding gestational age (p=0.480), birth weight (p=0.299), fraction of inspired oxygen (FiO2) prior to surfactant (p=0.220), oxygen therapy duration (p=0.306), progression to intubation (p=0.712), or length of Neonatal Intensive Care Unit stay (p=0.778). FiO2 variation before and after surfactant administration was higher in MIST group (14% vs 9%, p=0.078). No significant complications were reported with either technique.\nConclusions: MIST is a safe technique in preterm infants on nCPAP. This study shows similar outcomes with MIST and INSURE procedures, with a greater reduction in FiO2 requirements with MIST. Overall, MIST is less invasive and as effective as INSURE in preterm infants.","PeriodicalId":31313,"journal":{"name":"Nascer e Crescer","volume":"210 1","pages":"18-25"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nascer e Crescer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25753/BIRTHGROWTHMJ.V30.I1.19182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Minimally invasive surfactant therapy (MIST) is a surfactant administration procedure that intends to reduce intubations and associated risks. The aim of this study was to compare MIST with INtubation-SURfactant-Extubation (INSURE) technique.
Material and methods: Retrospective analysis (from January 2015 to June 2019) of preterm infants on nasal continuous positive airway pressure (nCPAP) treated with surfactant.
Results: Fifty-four preterm infants were included and divided in two groups: MIST (n=34) and INSURE (n=20). No significant differences were found between groups regarding gestational age (p=0.480), birth weight (p=0.299), fraction of inspired oxygen (FiO2) prior to surfactant (p=0.220), oxygen therapy duration (p=0.306), progression to intubation (p=0.712), or length of Neonatal Intensive Care Unit stay (p=0.778). FiO2 variation before and after surfactant administration was higher in MIST group (14% vs 9%, p=0.078). No significant complications were reported with either technique.
Conclusions: MIST is a safe technique in preterm infants on nCPAP. This study shows similar outcomes with MIST and INSURE procedures, with a greater reduction in FiO2 requirements with MIST. Overall, MIST is less invasive and as effective as INSURE in preterm infants.
微创表面活性剂治疗(MIST)是一种表面活性剂给药程序,旨在减少插管和相关风险。本研究的目的是比较MIST与插管-表面活性剂-拔管(INSURE)技术。材料与方法:回顾性分析2015年1月至2019年6月接受表面活性剂鼻腔持续气道正压通气(nCPAP)治疗的早产儿。结果:纳入54例早产儿,分为MIST组(n=34)和INSURE组(n=20)。两组间在胎龄(p=0.480)、出生体重(p=0.299)、表面活性物质使用前吸入氧(FiO2)比例(p=0.220)、氧治疗持续时间(p=0.306)、插管进展(p=0.712)或新生儿重症监护病房住院时间(p=0.778)方面无显著差异。表面活性剂给药前后,MIST组FiO2变化较高(14% vs 9%, p=0.078)。两种方法均无明显并发症。结论:MIST是一种安全的早产儿nCPAP技术。该研究表明,MIST和INSURE的结果相似,MIST更能降低FiO2要求。总的来说,在早产儿中,MIST的侵入性较小,与INSURE一样有效。